Business
This Week's New to The Street / Newsmax T.V. Broadcast, Seven Business Interviews Airing on October 24, 2021, Showtime 10-11 AM ET
This Week's New to The Street / Newsmax T.V. Broadcast, Seven Business Interviews Airing on October 24, 2021, Showtime 10-11 AM ET.
About this update from Epazz, Inc.
[{"type":"text","content":"\n NEW YORK, Oct. 22, 2021 (GLOBE NEWSWIRE) -- FMW Media's New to The Street / Newsmax T.V. announces the broadcasting line-up of its national syndicated 1- hour T.V. show this Sunday, October 24, 2021, airing time 10-11 AM ET. New to The Street's 254th T.V. show line-up, features seven interviews of the following Companies and their businesses representatives: 1). PetVivo Holdings, Inc.'s (NASDAQ: PETV) interview, Mr. John Lai, CEO & President. 2). Artificial Intelligence Technology Solutions, Inc.'s (OTCPINK: AITX) interview, Mr. Steve Reinharz, CEO. 3). Rego Payments Architectures, Inc.'s. (OTCQB: RPMT) interviews, Mr. Dan Aptor, Head of Strategy, and Ms. Julie Jatlow, partner FUSE Digital Marking firm. 4). Epazz, Inc.'s (OTCPINK: EPAZ) interview, Mr. Mike Manahan, Vice-president Communications. 5). GlobeX Data Ltd.'s (OTCQB: SWISF) (CSE: SWIS) (FRA: GDT) interview, Mr. Alain Ghiai, CEO. 6). Sekur's® (division of GlobeX Data, Ltd) \"SPECIAL SEGMENT\" interview, internet privacy expert Mr. Alain Ghiai, CEO. 7). TGI Solar Power Group, Inc.'s (OTCMKTS: TSPG) interview, Mr. Sam Epstein, Chief Operations Officer (COO). The New to The Street T.V. show airs the in-studio NASDAQ interview with Mr. John Lai, CEO & President, PetVivo Holdings, Inc. (NASDAQ: PETV). Talking with T.V.'s Host Jane King, Mr. Lai gives an overview of the Company's biomedical devices and its osteoarthritis treatment available to millions of dogs and horses. With about 17 new products in development at the Company, Mr. Lai gives examples of various products used for humans. PETV's vascular shunts show no clotting problems, a typical issue with current products in use. Another product development, their vascular stent, shows no thrombosis issues after 30-days of being applied, a specific problem related to existing products currently in the marketplace. At the recent veterinary conference in Las Vegas, John's says the Company's received very well. And at the Emerging Growth Conference, another attended venue allowed the Company to inform shareholders, potential shareholders, and industry professionals about the Spryng™ with OsteoCushion™ Technology injection. He explains how the US FDA views treatments and applications between humans and animals and the fundamental difference on a regulatory basis. He tells views to expect a feline...